[go: up one dir, main page]

AR117406A1 - Composición farmacéutica parenteral - Google Patents

Composición farmacéutica parenteral

Info

Publication number
AR117406A1
AR117406A1 ARP190100736A ARP190100736A AR117406A1 AR 117406 A1 AR117406 A1 AR 117406A1 AR P190100736 A ARP190100736 A AR P190100736A AR P190100736 A ARP190100736 A AR P190100736A AR 117406 A1 AR117406 A1 AR 117406A1
Authority
AR
Argentina
Prior art keywords
parenteral pharmaceutical
treatment
pharmaceutical composition
patients
neladenosone
Prior art date
Application number
ARP190100736A
Other languages
English (en)
Inventor
Pfeffer Michael Dr
Nicolai Janine Dr
Anlahr Johanna Dr
Erber Matthias Christian Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR117406A1 publication Critical patent/AR117406A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas parenterales que comprenden L-alanil-L-alaninato de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4-il]fenoxi}etilo, que también se conoce como bialanato de neladenosona, en forma de una de sus sales, un proceso para su preparación, su uso como medicamento, así como su uso para la prevención y/o el tratamiento de enfermedades cardiovasculares, por ejemplo para cardioprotección durante, y/o después de un evento cardíaco inducido por isquemia, por ejemplo después de una cirugía no cardíaca de mediano y alto riesgo, lesión por reperfusión en pacientes de STEMI, y tratamiento de pacientes agudos hospitalizados con empeoramiento de la insuficiencia cardíaca.
ARP190100736A 2018-03-22 2019-03-22 Composición farmacéutica parenteral AR117406A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18163467 2018-03-22

Publications (1)

Publication Number Publication Date
AR117406A1 true AR117406A1 (es) 2021-08-04

Family

ID=61763827

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100736A AR117406A1 (es) 2018-03-22 2019-03-22 Composición farmacéutica parenteral

Country Status (2)

Country Link
AR (1) AR117406A1 (es)
WO (1) WO2019180072A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
PT2389923E (pt) 2010-05-19 2013-03-28 Uni Pharma Kleon Tsetis Pharmaceutical Lab S A Formulação injectável estável de paracetamol pronta a usar
HUE044787T2 (hu) 2015-05-06 2019-11-28 Bayer Pharma AG Eljárás 2-{4-[2-({[2-(4-klórfenil)-1,3-tiazol-4-il]metil}szulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4-il] fenoxi}etil-L-alanil-L-alaninát-monohidroklorid elõállítására

Also Published As

Publication number Publication date
WO2019180072A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
CL2021002963A1 (es) Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer
CL2010001636A1 (es) (r,z)-5-(2-(3-aminopiperidin-1-il)-3-isopropoxibencilideno)tiazolidin-2,4-diona, (r,z)-5-(2-(3-aminopiperidin-1-il)bifenil-3-ilmetilen)tiazolidin-2,4-diona, o una sal de los mismos; composicion farmaceutica; uso para el tratamiento del cancer y para la inhibicion de quinasa pim.
CY1123346T1 (el) Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα
UY31244A1 (es) Profarmacos dipeptoides y su uso
CO2021013251A2 (es) Derivados de insulina sensibles a la glucosa
AR111178A1 (es) Inhibidor de la quinasa reguladora de la señal de apoptosis
EA201892746A1 (ru) Лечение гематологической злокачественной опухоли с помощью 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида
AR074471A1 (es) Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
BR112021024325A2 (pt) Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
CO2018002708A2 (es) Coterapia que comprende canagliflozina y fentermina para el tratamiento de la obesidad y de los trastornos relacionados con la obesidad
AR093188A1 (es) Sal y uso medico
MX2017016862A (es) Composicion farmaceutica estable para administracion oral.
AR117406A1 (es) Composición farmacéutica parenteral
CO6311076A2 (es) Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente
PE20180204A1 (es) Procedimiento para la preparacion de 2-4-[2-([2-(4-(clorofenil)-1,3-tiazol-4-il]metilsulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxietil-l-alanil-l-alaninato-monohidrocloruro
AR102248A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
MX2022005187A (es) Compuesto de ácido oxocarboxílico heterocíclico de cinco miembros y el uso médico del mismo.
CO2019005207A2 (es) Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética
AR120578A1 (es) DERIVADOS DE BENCILAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 (TGFbRI) / ALK5
EP4477224A4 (en) Pharmaceutical composition comprising allopurinol, febuxostat, or a corresponding pharmaceutically acceptable salt for the prevention or treatment of cardiovascular disease in a subject with elevated blood uric acid levels
Arnolds et al. Comment on Retnakaran et al. Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014; 37: 3270–3278
AR121038A1 (es) Derivados de insulina sensibles a glucosa
Lee et al. Similar Morphology, but Different Function: Acute Improvement of Myocardial Longitudinal Strain after Percutaneous Transcatheter Aortic Valve Implantation Therapy in a Severe Aortic Stenosis Patient
AR110371A1 (es) Formulación de comprimido farmacéutico

Legal Events

Date Code Title Description
FB Suspension of granting procedure